Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | Phase Ib/IIa study of AZD4573 and acalabrutinib in patients with R/R DLBCL

Gareth Gregory • 11 Dec 2022
ASH 2022
Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Acalabrutinib AZD4573 BTK inhibitors

Gareth Gregory, MBBS, PhD, FRACP, FRCPA, Monash University, Monash Health, Melbourne, Australia, discusses a Phase Ib/IIa study evaluating AZD4573, a novel CDK9 inhibitor, in combination with acalabrutinib in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (R/R DLBCL; NCT04630756). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Roche: Consultancy, Honoraria, Speakers Bureau; Novartis: Consultancy; Janssen: Consultancy.

More from Gareth Gregory

0:57
Outcomes of patients with double-hit lymphoma treated with CAR-T therapy
Gareth Gregory • 11 Dec 2022
1:11
Evaluating salvage radiotherapy in patients with DLBCL
Gareth Gregory • 11 Dec 2022
1:26
Insights into the diagnosis of primary CNS lymphoma and challenges in this space
Gareth Gregory • 11 Dec 2022

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals